linjc16/ctgov huggingface dataset:
Nutritional and Functional Assessment of Patients Undergoing Surgery Due to Gastrointestinal Cancer (NUFAGI).

Study Overview
=================
Brief Summary
-----------------
Several patients that suffer from gastrointestinal (GI) cancer are characterized by malnutrition and impairment of their functional status. The aim of the present study is to evaluate the nutritional condition of patients undergoing surgery due to GI cancer and compare it with their functional status. All consecutive patients with esophageal, gastric, colorectal, hepatocellular, pancreatic and biliary cancer, that underwent a surgical operation will be included. Demographic characteristics, nutritional assessment and anthropometric measurements of the patients will be recorded.

Official Title
-----------------
Nutritional and Functional Assessment of Patients Undergoing Surgery Due to Gastrointestinal Cancer (NUFAGI): a Prospective Cohort Study.

Conditions
-----------------
Gastrointestinal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing a surgical operation due to esophageal, gastric, colorectal, hepatocellular, pancreatic and biliary cancer. Exclusion Criteria: Under 18 years old or above 99 years old. Surgery due to benign conditions.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative morbidity. | Complications after surgery. | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality. | Number of deaths. | 30 days | 
| Disease stage | TNM after histological examination | 1 month | 
| Recurrence | Disease recurrence | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nutritional status, functional status, gastrointestinal cancer
COVID-19 Vaccines and the Menstrual Cycle

Study Overview
=================
Brief Summary
-----------------
The study aimed to explore the effect of different COVID-19 vaccines on menstrual cycle

Detailed Description
-----------------
This is a descriptive cross-sectional study that took place between September 2021 and December 2021. The study aimed to explore the effect of different COVID-19 vaccines on menstrual cycle. It used an anonymous questionnaire distributed via social media platforms; Facebook, Twitter, and WhatsApp across different cities of Jordan. A total of 732 responses were received with a 59% response rate. The questionnaire was distributed over four months directed at women who have received at least one dose of the COVID-19 vaccine and who live in Jordan. It took 10 minutes to complete all the questions. Data collection did not involve direct contact with participants to prevent the spread of COVID-19.

Official Title
-----------------
COVID-19 Vaccines and the Menstrual Cycle; a Cross-sectional Study

Conditions
-----------------
Menstrual Irregularity

Intervention / Treatment
-----------------
* Biological: Naser Al-Husban


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years and older less than 40 years healthy women received covid-19 vaccine Exclusion Criteria: women who did not receive the vaccine those living outside Jordan (those cannot fill the form) and during analysis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Naser Al-Husban|COVID-19 vaccines|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| significant changes in the menstrual cycle after vaccination | changes that involve bleeding amount or pain | 6 months |
A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

Official Title
-----------------
A Non-interventional Study and Its Clinical Relevance With Central Nervous System Metastatic Epidermal Growth Factor Receptor Mutation Positive Non-small Cell Lung Cancer

Conditions
-----------------
NSCLC

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be ≥18 years. Provision of fully informed consent prior to any study specific procedures. Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically. The mutations above may exist alone or together. Patients must have untreated advanced Non-Small Cell Lung Cancer (NSCLC). According to the RECIST 1.1 standard, the patient must have at least one measurable lesion. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Progression-free survival (PFS) is defined as the time from beginning of study treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy prior to progression. | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Central nervous system (CNS) progression-free survival | CNS PFS is defined as the time from beginning of study treatment until the date of objective progression of central nervous system or death (by any cause in the absence of CNS progression), regardless of whether the patient withdraws from study treatment or receives another anti-cancer therapy prior to progression. | 2 years | 
| Objective Response Rate | Defined as the number (%) of patients with response of Complete Response or Partial Response | 2 years |
Respiratory Oscillometry for the Prediction of Bronchopulmonary Dysplasia

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about the correlation between respiratory system reactance, as assessed by respiratory oscillometry, and respiratory outcomes in preterm infants born before 32 weeks of gestation. The main question it aims to answer is if the reactance z-score at 7 postnatal days adds to relevant clinical factors in the prediction of bronchopulmonary dysplasia. Participants will receive respiratory oscillometry measurements at 7 ± 2 postnatal days.

Official Title
-----------------
Relationship Between Respiratory System Reactance Assessed by Respiratory Oscillometry and Respiratory Outcomes in Very Preterm Infants

Conditions
-----------------
Bronchopulmonary Dysplasia

Intervention / Treatment
-----------------
* Diagnostic Test: Respiratory Oscillometry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: born before 32 weeks post-menstrual age Exclusion Criteria: congenital abnormalities Inherited disorders of metabolism

Ages Eligible for Study
-----------------
Minimum Age: 5 Days
Maximum Age: 9 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| no bronchopulmonary dysplasia<br>Group of patients who do not receive the diagnosis of bronchopulmonary dysplasia defined as the need for respiratory support at 36 weeks post-mentrual age | Diagnostic Test: Respiratory Oscillometry<br>* Measurement of respiratory system reactance by respiratory oscillometry<br>|
| bronchopulmonary dysplasia<br>Group of patients developing bronchopulmonary dysplasia defined as the need for respiratory support at 36 weeks post-menstrual age. | Diagnostic Test: Respiratory Oscillometry<br>* Measurement of respiratory system reactance by respiratory oscillometry<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Respiratory system reactance (Xrs) at the clinical positive end-expiratory pressure | Xrs will be expressed in z-score using reference equation for very preterm infants | Xrs will be measured at 7 days of life | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Respiratory system reactance (Xrs) at the clinical positive end-expiratory pressure and ± 2 cmH2O | Xrs will be expressed in cmH2O*S/L | Xrs will be measured at 7 days of life | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Respiratory oscillometry, Respiratory system reactance, Lung mechanics, Infant lung function testing
Validity and Reliability of the Smart Speed Device

Study Overview
=================
Brief Summary
-----------------
The Smart Speed device developed at Zafer Teknopark in Turkey was developed to objectively assess reaction time. The aim of this study was to evaluate the validity and reliability of the Smart Speed device in comparison with BlazePod and Nelson Reaction Test.

Detailed Description
-----------------
The capacity to perceive, analyze, and react to a signal is referred to as reaction time. Reaction time is influenced by many factors such as visual and auditory factors. It is also influenced by individual factors such as age, gender, body mass index, attention and fatigue. Having reaction time within normal limits is very important for maintaining activities of daily living. BlazePod is a valid and reliable device for the assessment of reaction time. The Nelson Reaction test is also a valid and reliable test frequently used in the clinic for the assessment of reaction time due to its simple and rapid application. The Smart Speed device developed at Zafer Teknopark in Turkey was developed to objectively assess reaction time. The aim of this study was to evaluate the validity and reliability of the Smart Speed device in comparison with BlazePod and Nelson Reaction Test.

Official Title
-----------------
Investigating the Reliability and Validity of the Smart Speed Device

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Other: Validity and reliability study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Without having systemic disease To be able to speak Turkish language Exclusion Criteria: Having a problem that affects physical performance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 24 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Validity and reliability study|Test-retest method will be used to assess reliability. For this purpose, participants will be re-evaluated one week later with the Smart Speed device. For validity assessment, concurrent validity and agreement between measurements will be evaluated. Concurrent validity will be assessed by correlation analysis and agreement between measurements will be assessed by Bland Altman.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of reaction time | To determine the validity and reliability of the Smart Speed device in assessing reaction time | 15 minutes |
Homeopathic Treatment of Children Suffering From PFAPA

Study Overview
=================
Brief Summary
-----------------
Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome is frequently diagnosed in young children. Fevers recurring at a nearly predictable rate every three to eight weeks are the signature symptom of PFAPA syndrome. PFAPA is an acquired autoinflammatory disorder, which recurs in association with at least one sign of aphthous stomatitis, pharyngitis, and cervical lymph node enlargement. The aim of this retrospective case report is to gain an impression of the course of disease during individualized homeopathic treatment in children suffering from PFAPA.

Detailed Description
-----------------
In this retrospective study, the investigators collected the history and symptoms of 13 consecutive PFAPA patients. The investigators also described the individually chosen homeopathic medicinal products (HMPs) used, as well as the course of the disease. Clinical outcome of case reports was assessed using the Modified Naranjo Criteria for Homeopathy-Causal Attribution Inventory. Eight points are taken as the threshold for the possible correlation between homeopathic therapy and improvement of symptoms or cure in chronic cases

Official Title
-----------------
Homeopathic Treatment of Children Suffering From PFAPA: a Retrospective Case Series.

Conditions
-----------------
Periodic Fever Syndrome

Intervention / Treatment
-----------------
* Drug: Homeopathic Globule


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children suffering from fever with at least one of the symptooms of PFAPA besides fever Exclusion Criteria: Parents not willing to sign informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Children suffering from PFAPA<br>Children suffering from periodic fever, with at least one of the following symptoms: aphthous stomatitis, pharyngitis, cervical adenitis | Drug: Homeopathic Globule<br>* Homeopathic globules were administered after careful anamnesis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Periodic fever flares | Appearance of periodic fever flares | 30 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PFAPA, periodic fever, homeopathy, Naranjo criteria
A (5-5-5-8) Technique for Laparoscopic Cholecystectomy

Study Overview
=================
Brief Summary
-----------------
The aim of this current study is to investigate the effectiveness and safety of a novel technique which is the 5-5-5-8 where the camera port is 5 mm.

Detailed Description
-----------------
More than 50 different LC procedures are described in the literature, mostly as a result of changes made by surgeons to enhance cosmetic and postoperative results. Some adjustments include port size and/or number reductions relative to conventional LC usage. Each of these methods has benefits and drawbacks, and each one is appropriate for usage in particular circumstances. The aim of this current study is to investigate the effectiveness and safety of a novel technique which is the 5-5-5-8 where the camera port is 5 mm.

Official Title
-----------------
A (5-5-5-8) Technique for Laparoscopic Cholecystectomy

Conditions
-----------------
Cholecystitis; Gallstone, Cholecystolithiasis, Cholecystitis, Chronic

Intervention / Treatment
-----------------
* Procedure: 5-5-5-8 technique
* Procedure: 10-10-10-5 technique


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged > 18 years Patients eligible for LC during the study period Exclusion Criteria: refused to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 5-5-5-8 group<br>In this group, the new 5-5-5-8 technique of laparoscopic cholecystectomy will be done. | Procedure: 5-5-5-8 technique<br>* the new technique of 5-5-5-8 for laparoscopic cholecystectomy<br>|
| Active Comparator: Control<br>In this group, the 10-10-5-5 technique of laparoscopic cholecystectomy will be done. | Procedure: 10-10-10-5 technique<br>* the standard technique of 10-10-10-5 for laparoscopic cholecystectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of the operation | Duration of the operation in minutes | 1 hour | 
| Number of participants with Conversion to open surgery | Number of participants with Failure of the technique and conversion to open surgery | 1 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of port site infection | incidence of infection of the port site | 1 month | 
| Incidence of port site hernia | Incidence of hernia of the port site | 6 weeks |
Quantifying Disease Progression in LBSL

Study Overview
=================
Brief Summary
-----------------
Leukoencephalopathy with brain stem involvement and lactate elevation (LBSL) is a genetic disorder caused by biallelic mutations in the DARS2 gene that encodes mitochondrial aspartyl tRNA synthase.(1, 2) It is characterized by typical abnormalities on MRI of the brain and spinal cord.(3) Clinically, the disorder is heterogeneous and can present in the neonatal period, later in childhood or even in adults.(3) In general it can be stated that the earlier presentations are characterized by rapid progression leading to severe disability and death. Presentation at a later age is typically characterized by a more benign disease course, although considerable disability is common. Clinically, the disease presents as a slowly progressive myelopathy with mainly involvement of the corticospinal tracts and the dorsal columns. Although the natural history has been studied in large cohorts, the rate of progression has not been systematically studied with clinimetric outcome scales or potential surrogate outcomes for spinal cord disease.

Official Title
-----------------
Quantifying Disease Progression in Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation (LBSL)

Conditions
-----------------
LBSL, Leukoencephalopathies

Participation Criteria
=================
Eligibility Criteria
-----------------
In order to be eligible to participate in this study, a subject must meet all of the following criteria: Age > 16 years Definite diagnosis of LBSL confirmed by DARS2 mutation analysis. Able to understand Dutch or English and provide informed consent. No contra-indications for MRI of brain and spinal cord. Subjects eligible to participate as healthy controls must meet all of the following criteria: Willing to visit the hospital 16 years or older Provision of written informed consent to participate in the study obtained from the participant For the MRI controls: - No contra-indications for MRI of the brain and spinal cord A potential subject (patient or healthy control) who meets any of the following criteria will be excluded from participation in this study: Unable to visit the hospital for the follow-up visits Co-existing neurological disease that can cause pyramidal tract signs making interpretation of acquired data difficult (for instance, multiple sclerosis, stroke, etc)

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome is disease progression on all parameters | disease progression | 5 years |
Visual Outcomes of Functional Intraocular Lenses in Cataracts

Study Overview
=================
Brief Summary
-----------------
This is a prospective, multi-center, randomized comparative study. The purpose of the study is to evaluate and compare the objective and subjective visual outcomes of different types of functional intraocular lenses (IOLs) in patients.

Detailed Description
-----------------
Analyzing the subjective and objective visual outcomes and related factors following the implantation of various types of intraocular lenses（bifocal, trifocal, extended depth of focus (EDOF), and astigmatism-correcting intraocular lenses), exploring the advantages, disadvantages, and suitable patient populations for different types of intraocular lenses, analyzing the factors affecting postoperative visual quality, and providing guidance to better assist patients with diverse needs in clinical settings, aiming to offer multidimensional postoperative visual quality.

Official Title
-----------------
Visual Outcomes of Different Types of Functional Intraocular Lenses in Cataract Patients

Conditions
-----------------
Cataract, Visual Quality

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cataract age > 18 years Exclusion Criteria: amblyopia; previous ocular surgery; ocular pathologies such as diabetic retinopathy, macular degeneration, glaucoma with field defects; requirements for further ocular surgery (other than Nd:YAG capsulotomy) or retinal laser treatments during the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| uncorrected distance visual acuity (UDVA) | uncorrected visual acuity at 5 m | one year | 
| best corrected distance visual acuity (BCVA) | corrected visual acuity at 5 m | one year | 
| uncorrected near visual acuity (UNVA) | uncorrected visual acuity at 40 cm | one year | 
| uncorrected intermediate visual acuity (UIVA) | uncorrected visual acuity at 60 cm | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HOAs | high order aberrations such as coma | three months | 
| Strehl Ratio | The derivative of point spread function (PSF) | three months | 
| objective visual quality | The modulation transfer function (MTF) curve | three months | 
| contrast sensitivity | Contrast sensitivity were obtained from the Functional Vision Analyzer | three months | 
| visual functions | Visual functions were obtained from the OCULUS Binoptometer 4P | three months | 
| IOL condition | IOL condition were obtained from the wavefront mode of the OPD-Scan III aberrometer. | three months | 
| subjective satisfaction | Satisfaction Questionnaire | three years | 
| photic phenomena | Questionnaire of photic phenomena | three years |